NEW YORK (GenomeWeb News) – French drug firm Servier has licensed non-exclusive rights to use Cellectis' π10 modified cell lines for high-throughput screening efforts.

The new agreement follows a recently concluded research pact between the firms that began in 2007.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.